Size at birth, postnatal weight gain, and adult risk for type 2 diabetes may reflect environmental exposures during developmental plasticity and may be mediated by epigenetics. Both low birth weight (BW), as a marker of fetal growth restraint, and high birth weight (BW), especially after gestational diabetes mellitus (GDM), have been linked to increased risk of adult type 2 diabetes. We assessed DNA methylation patterns using a bead chip in cord blood samples from infants of mothers with GDM (group 1) and infants with prenatal growth restraint indicated by rapid postnatal catch-up growth (group 2), compared with infants with normal postnatal growth (group 3). Seventy-five CpG loci were differentially methylated in groups 1 and 2 compared with the controls (group 3), representing 72 genes, many relevant to growth and diabetes. In replication studies using similar methodology, many of these differentially methylated regions were associated with levels of maternal glucose exposure below that defined by GDM [the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study] or were identified as changes observed after randomized periconceptional nutritional supplementation in a Gambian cohort characterized by maternal deprivation. These 
Low BW in infants, an indication of a poor intrauterine environment, has also been associated with an increased risk of type 2 diabetes in later life (4) . Fetal growth restraint followed by rapid postnatal weight gain has been consistently associated with risk of childhood obesity and insulin resistance (5, 6) , whereas a low ponderal index at birth, associated with short stature and impaired ␤-cell function, is associated with type 2 diabetes risk (7) . It has been hypothesized that both low-and high-BW associations reflect phenotypic adaptations to environmental stimuli and early nutritional exposures that favor survival (termed developmental plasticity; ref. 8) . The mechanism may be related to changes in the epigenome, such as DNA methylation at CpG islands (9) . Such epigenetic modifications that influence gene activity may allow favorable adaptations [e.g., protection against undernutrition during pregnancy or early postnatal life (the thrifty phenotype); ref . 10] . However, this phenotype in the context of a richer postnatal diet may ultimately have an adverse effect and contribute to an increased risk of adult metabolic diseases (11) .
The first empirical data to support the hypothesis that early-life environmental conditions can cause epigenetic changes in humans that persist throughout life came from a study by Heijmans et al. (12) , who found that individuals with prenatal exposure to famine during the Dutch Hunger Winter (1944 -1945) had, 6 decades later, less DNA methylation of the imprinted IGF2 gene compared with their unexposed, same-sex siblings. More recently, Van Abeerlen et al. (13) found the first direct evidence that women exposed to the 1944 -1945 Dutch famine had an increased risk of adult type 2 diabetes. In addition, our group identified the importance of periconceptional nutrition in a Gambian population, where diet is nutritionally depressed during the wet season. We found that periconceptional maternal micronutrient supplementation was related to epigenetic change in DNA in newborn cord blood (14, 15) .
Currently, there are no data on the association of diverse prenatal exposures, GDM, and growth restraint with increased risk for type 2 diabetes through common epigenetic pathways. To explore this hypothesis, we undertook DNA methylation studies of cord blood from infants of mothers with GDM and infants showing rapid postnatal growth after prenatal growth restraint. Replication studies were performed in 2 additional cohorts: 1 with prenatal exposure to glucose levels below those normally associated with GDM (16, 17) and a previously described cohort with extreme prenatal nutritional growth restriction (14) .
MATERIALS AND METHODS

Patient identification and DNA collection
Our initial studies were based on 3 groups of infants nested within the Cambridge Baby Growth Study (CBGS), which have been previously described (18, 19) .
Group 1 included infants of GDM pregnancies. Infants of mothers with abnormal glucose tolerance at 28 wk of pregnancy were identified by using contemporary World Health Organization (WHO) guidelines. (Clinical characteristics are presented in Table 1 ).
Group 2 included infants exhibiting prenatal growth restraint, as indicated by rapid postnatal catch-up growth, which was defined by a gain in weight standard deviation score (SDS) of Ͼϩ0.67 between birth and age 12 mo (5). Weight SDS was calculated by comparison to the 1990 British growth reference (20) and LMS Pro software (21) . The SDS at birth was adjusted for gestational age, and the result was subtracted from weight SDS at 12 mo of age, to provide an index of change in weight SDS from 0 to 12 mo (Table 1) . Group 3 included control infants who were not born after a GDM pregnancy and who showed little deviation in their postnatal weight centile position between birth and 12 mo of age, as defined by a change in weight SDS between Ϫ0.5 and 0 (Table 1) .
In all 3 groups, cord blood was obtained at delivery (Table  1) , and DNA was extracted by using standard methods. Samples were prepared at 50 ng/l. In total, DNA was obtained from 20 female catch-ups (FCU group), 20 male catch-ups (MCU group), 8 females born to mothers with GDM (FD group), 8 males born to mothers with GDM (MD group), 20 female controls (FC group), and 20 male controls (MC group).
We sought independent replication in two other cohorts with cord blood DNA. In collaboration with the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study (16, 17) , cord blood was obtained from 36 infants from Barbados, 18 of whom were born to mothers at the lower end of the HAPO fasting plasma glucose distribution and 18 to mothers at the high end of the glucose distribution (Table 1) . A comparison of methylation patterns of genes from the high group vs. the low group was performed. None of the mothers admitted smoking or alcohol consumption during pregnancy. The second comparison was to cord blood DNA that had been previously reported (14) .
Microarray methylation analysis
DNA (1 g) from each infant was initially treated with sodium bisulfite with the EZ DNA methylation kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's instructions. The treated DNA was applied to the HumanMethylation27 BeadChip (Illumina, San Diego, CA, USA), which quantifies DNA methylation at up to 27,578 CpGs located in promoters associated with ϳ14,000 genes. Whole-genome amplification, labeling, hybridization, and scanning (on the BeadArray scanner) were performed in line with Illumina protocols.
Sample quality control
Methylation results for samples were subjected to quality control by multidimensional scaling [principal component analysis (PCA)] and unsupervised hierarchical clustering analysis of CpG sites that showed variable methylation, as defined by standard deviation/mean methylation Ͼ 0.1. Poor-quality samples were identified and excluded from subsequent analyses. Figure 1A shows the clustering of all samples (by group), based on data from 26,486 CpG loci with sd/mean Ͼ 0.1. DNA quality was the principal component separating the samples and highlighting 14 failed samples. Figure 1B shows the principal component separating males and females based on data from 1085 CpG loci on the X chromosome, with sd/mean Ͼ0.1. Two samples from male infants (19904816, 19921765) were identified that showed maternal cell contamination; this analysis also confirmed the other 14 failed samples; Fig. 1C shows the results of unsupervised hierarchical clustering which identified the same 14 failures.
In GenomeStudio (Illumina), histogram plots showing the average methylation score values (AVG_Beta) for the X chromosome loci of each sample provided confirmation that samples 19904816 and 19921765, both from males, showed a female pattern suggesting significant contamination with maternal blood. Probes with a detection value Ͼ0.05 were also removed from the analysis. The samples excluded from each group were 2 from FD, 3 from MD, 2 from FCU, 1 from MCU (with maternal contamination), 3 from MC (1 with maternal contamination), and 5 from FC.
Statistical analysis
Sample analysis was performed with the methylation module of the Illumina Genome Studio software, as described by Khulan et al. (14) . Methylation ratios were calculated with the following formula: ␤ ϭ C/(CϩTϩ100), where C is the fluorescence associated with methylated sites and T that of the unmethylated sites. A false-discovery rate (FDR) correction was applied to the data. Changes in methylation between the test and control groups were measured by the difference in ␤ values (⌬␤). To identify significant differentially methylated CpGs, cutoff values of Ϯ10% ⌬␤ at P Ͻ 0.001 (equivalent to a DiffScore of Ͼ30 or ϽϪ30 on the Illumina significance threshold scale) were set. (FDR-corrected P value equivalents were used, where 30 or Ϫ30 is equivalent to Pϭ0.001, 40 or Ϫ40 is Pϭ0.0001, and so on).
Previous studies report the importance of evaluating males and females separately (14) . Furthermore, 907 loci on the HumanMethylation27 BeadChip overlap with single-nucleotide polymorphisms (SNPs; ref. 22) , which could confound the assessment of methylation change if distribution of the SNP alleles was skewed between the test patients and controls. Ten of our significantly differentially methylated loci overlap with known SNPs (summarized in Table 2 ). In all cases with a C/T or A/G polymorphism, it is the T or the A that is the minor allele and the minor allele frequencies (MAFs) range from 0.0059 to 0.31. For methylation to be affected by the SNP, an excess of the minor allele in one of the groups is needed.
Of the loci overlapping SNPs, 3 distinct methylation indices were visible for cg20022541_C14orf152 (FD group) and cg03606258_GNAS (MCU group) and 2 indices for cg17977362_FLJ45964 (FD and MD groups) and cg18951427_ACYP2 (MCU group). With the exception of cg17977362_FLJ45964 (FD group), these were present for both cases and controls and therefore not skewed; the methylation differences therefore still should be valid. For cg17977362_FLJ45964 [MAF/minor allele count (MAC): Tϭ0.0622/136], individual sequencing of DNA from the FD, MD, FC, and MC groups was performed.
Gene ontology
Ontologies of those genes associated with significant differentially methylated CpGs were determined by using U.S. National Center for Biotechnology Information (NCBI; Bethesda, MD, USA; http://www.ncbi.nlm.nih.gov/) Gene, Online Mendelian Inheritance in Man (OMIM), and PubMed databases and Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7. (http://david. abcc.ncifcrf.gov/).
Bisulfite mass array validation
A small selection of loci [PON1, NFE2, PKHD1, and GSTM5 (2 loci)], that were found to be significant in the microarray data and that harbored biological candidate genes were validated in duplicate with the MassArray (Sequenom, San Diego, CA, USA) system. Primers were designed as described elsewhere (14) to amplify target regions containing the CpG of interest, avoiding known SNPs ( Table 3) . Samples were spotted onto SpectroChips (Sequenom) for analysis by mass spectrometry (Bruker MassArray Compact Analyzer; Sequenom). Complete conversion was verified with the R-package MassArray, and data were output with EpiTyper software (Agene Bioscience, San Diego, CA, USA). Sequenom MassArray analysis was used to validate the changes in methylation highlighted by the Illumina chip for the 5 loci (Fig. 2) . A good correlation was confirmed between the two methods (R 2 ϭ0.538682; PϽ3.6 EϪ28), which infers that the global data from the array are a reliable assessment of DNA methylation across the genome.
RESULTS
Differentially methylated CpG loci and annotation of associated genes
In total, the comparison between the patient cohorts revealed 75 differentially methylated Through combined analysis of the Gene, PubMed, OMIM, and DAVID databases, functional annotation of significantly differentially methylated genes was determined and classified into the disease categories listed in Table 4 , including disease-associated mutations. Nineteen genes were identified that have an association with metabolic disease and 24 genes with known relevance to disorders such as diabetes and weight disorders.
Differentially methylated loci shared between different study cohorts
The differentially methylated loci shared among the cohorts in this and 2 previous studies (HAPO and Gambian) are shown in Fig. 3 . HAPO results (16) compared to our CBGS samples (18) are summarized in Table 5 the Gambian data were published in our prior study (14) . Several shared patterns between cohorts were identified.
Eight differentially methylated loci (TERF2IP, NDUFA1, SUSD1, C3orf31, PBK, C6orf96, RPL17, and ACYP2) were shared between the GDM and MCU cohorts (Fig. 3 ). Of these, only TERF2IP was significant in the female GDM infants (FD group). Four of these loci (TERF2IP, SUSD1, C6orf96, and ACYP2) showed significant differential methylation in the Gambian study.
Four GDM differentially methylated loci were shared between the males and females (FD and MD groups; Fig. 3 ). Three of these were also significant in the HAPO (MGC3207, OR2L13, and FLJ45964) and Gambian (MGC3207, FLJ45964, and TERF2IP) studies.
One differentially methylated locus (C14orf39) was shared between the males and females in the prenatal growth restriction cohorts (FCU and MCU groups).
The following additional differentially methylated loci were shared between cohorts in the current study and the HAPO and Gambian data: MD group and HAPO study: MEOX1 and GSTM5; MD group and Gambian study: MEOX1, GPATCH2, and NYX; FD group and HAPO study: INSL4; FD group and Gambian study: EPS8L1, TAS2R49, PSMD5, and NFE2; FCU group and Gambian study: RASGRP3 and C7orf9; and MCU group and Gambian study: GNPNAT1, IL27RA, 
FLJ25801, TMEM79, SMYD4, REG1A, POR, IFNGR2, GNAS, BDH2, and LCK.
The observation is that there are groups of differentially methylated loci found in all of these different studies that may influence shared genetic pathways.
Differentially methylated CpG loci showing between 5 and 10% methylation change
To identify other loci with appropriate biological functions, we lowered the threshold of differential methylation change (Ϯ5-10%) 
DISCUSSION
This pilot study examined the effects of various adverse intrauterine environments on DNA methylation at birth, by studying infants exposed to GDM or to prenatal growth restriction, as indicated by subsequent postnatal catch-up growth. We found that many genes associated with significantly differentially methylated CpGs were common to both exposures, suggesting that these separate developmental trajectories to adult disease have shared biological mechanisms.
Differentially methylated loci shared between infants of mothers with GDM and infants with growth restriction
Eight loci were common to the offspring of mothers with GDM and infants with growth restriction, but were restricted to the male cohorts only. The genes associated with significant differentially methylated CpGs are important, as both patient cohorts are at risk for the development of diabetes, suggesting that regulation of some of the same gene pathways may be involved, the basis of our hypothesis. Of particular interest are ACYP2 (also significant in the Gambian study; ref. 14) , associated with coronary artery disease (24) , and C3orf31, a mitochondrial translocator assembly and maintenance protein, with a previously reported intergenic SNP between this gene and VGLL4 shown to be associated with insulin resistance (25).
Differentially methylated loci shared between males and females
Four significant loci, in common in both the male and female offspring of mothers with GDM, represent OR2L13, FLJ45964, MGC3207, and TERF2IP, suggesting that these would be particularly good candidates. The first locus cg20507276 (OR2L13), the most significant hypomethylated locus in the MD group, was also hypomethylated in the FD and MCU groups (⌬␤ϭ Ϫ7.6%). Conversely, it was hypermethylated in female offspring from the HAPO study. OR2L13 encodes an olfactory receptor involved in the perception of smell (NM_175911.2; RefSeq, July 2008; U.S. National Institutes of Health, Bethesda, MD, USA; https://cgwb.nci.nih.gov/). Locus cg17977362 (FLJ45964), the most significant hypermethylated locus in the FD group, was surprisingly hypomethylated in the MD group. FLJ45964 hypomethylation was also seen in males in the HAPO study, but methylation increased with age in the Gambian female unsupplemented group (representing infants exposed to a poor nutritional environment). The significant methylation at cg17977362 is confounded by the presence of an SNP (MAF/MAC: Tϭ0.0622/136). It is therefore difficult to assess the extent of methylation change, particularly as sequence analysis of unconverted DNA revealed that all individuals with apparent decreased change in methylation on the array carried the minor allele (T), which would thus affect the binding of the bead on the chip to sample DNA, as unmethylated beads bind to GT and methylated beads bind to GC. However, that the minor allele was present in these patients at a higher than expected frequency may be significant, since other closely linked SNPs at this locus have been associated with diabetes mellitus (25). Little is known about the protein potentially encoded at the FLJ45964 locus.
Two other loci, cg16474696 (MGC3207) and cg08585897 (TERF2IP), were hypomethylated in in- fants after GDM pregnancies. Locus cg16474696 (MGC3207) was also found to be hypomethylated in the FCU infants. MGC3207 interacts with MRI1 and is thought to be involved in the transfer of methyl groups, including DNA methylation. It is therefore a good candidate for mediator of epigenetic alterations of other loci. Differential methylation of the locus associated with TERF2IP was also identified in the MCU infants and the Gambian study (14) . The gene encodes a protein involved in regulation of telomere length, and genome-wide association studies (GWASs) have identified SNPs in the intergenic region between TERF2IP and RPL18P13 associated with cardiac arrhythmia (26) .
Only 1 locus (cg27398547) was in common to both sexes in the catch-up analyses. It represents C14orf39 and was hypermethylated (compared to controls) in the females but hypomethylated in the males. In a large human GWAS, an SNP near this gene was found to be associated with height (27) .
Differentially methylated regions associated with carbohydrate metabolism and obesity
Several significant differentially methylated CpGs from both the GDM and growth-restricted infants were associated with diabetes, irregular insulin secretion, or both.
In GDM infants, POU2F1 has multiple variants linked to a risk of type 2 diabetes (28); PON1 activity is significantly decreased in coronary artery disease and in diabetic patients (29) and also has polymorphisms associated with type 2 diabetes (30); NCB5OR showed impaired glucose tolerance in null mice (31); mutations in CP cause aceruloplasminemia, which results in iron accumulation and tissue damage and is associated with diabetes and neurological abnormalities (32) ; ENO2 encodes a neuron-specific enolase that is detected in the pancreatic nerve fibers and Langerhans islets (33) ; GPR42 is expressed mainly in pancreatic ␤ cells and mediates insulin secretion (34) ; NFE2 (also, the Gambian study) has an SNP just below genomewide significance in a study looking at waist circumference, a risk factor for diabetes and cardiovascular disease, whereas PKHD1 was significant (35) ; NHLH2 is linked to adult-onset obesity in knockout mice (36, 37) ; AGTR2 has a polymorphism associated with difficulty in improvement of obesity-related metabolic parameters through dietary intervention in obese women (38) ; and GPATCH2 (also, the Gambian study) may reduce the risk of death in Africans with type 2 diabetes who are on dialysis (39) .
In infants with growth restriction (also, the Gambian study), RASGRP3 has SNPs implicated in the abnormal vascular responsiveness to endothelin 1 and angioten- sin II in diabetic hypertensive rats (40) , and REG1A encodes a protein that is secreted by the exocrine pancreas and is associated with islet cell regeneration. Increased levels of the Reg1␣ protein have also been observed in patients with type 1 or 2 diabetes, antiReg1␣ antibodies were found in 47% of patients with type 1 diabetes (41), and GNPNAT1 is involved in amino sugar and the nucleotide sugar metabolism KEGG pathway (ID hsa00520).
Particularly relevant candidates with less stringent methylation changes (5-10%) include LEP and LEPR, both hypermethylated in the MCU cohort. Leptin regulates body weight by acting through its receptor and is part of a pathway that inhibits food intake. Mutations are associated with obesity (42) , and it has also been linked to type 2 diabetes (43) . ADCY3 was hypomethylated in the MCUs and is known to be associated with type 2 diabetes and susceptibility to obesity (25, 44), and GLP1R was hypomethylated in the MCUs, with expression that is negatively associated with DNA methylation of GLP1R in human pancreatic islets (45) . HP (FCUs), LTA (MCUs), and ACP1 (FCUs) have been linked with metabolic parameters in, or susceptibility to, type 1 diabetes (46, 47) . Anti-CD38 (FCUs) autoantibodies are more prevalent in long-standing than in new-onset type 1 diabetes and are more prevalent in type 2 than in type 1 diabetes (48).
Differentially methylated loci associated with growth and development
Loci linked to growth or fetal development also showed differential methylation. In the offspring of mothers with GDM, ESX1 was hypomethylated in the females. It is a placentally expressed homeobox gene that may have a role in the growth control mechanism of the fetus, through its effect on placental function (49) . Thymine DNA glycosylase (TDG) activity is essential for active demethylation and embryonic development (50) . In infants with growth restriction, GNAS was hypermethylated in MCUs and is an imprinted gene shown to have decreased expression in a microarray study of intrauterine growth restriction (51) . Microdeletions in the region of this gene have been associated with pre-and postnatal growth retardation (52) . In addition, in the Gambian study (14) , there was a change in methylation of GNAS after birth that was affected by micronutrient supplementation, and, in the sister study targeting imprinted genes, there was significant reduction in methylation at the GNASAS differentially methylated region in female infant blood but not in cord blood (15) . Another gene is HOXA4. HOX genes are involved in embryonic development, and HOXA4 encodes a DNA-binding transcription factor that may regulate gene expression, morphogenesis, and differentiation (NM_002141.4; RefSeq).
Location of CpGs
It was also interesting that 47.2% (34/72) of the genes had CpG loci outside of CpG islands compared to 25.4% on the chip as a whole. This finding suggests that a high proportion of lone promoter CpGs respond to environmental factors and could indicate the important functional elements within the affected promoters. This observation is similar to that in our Gambian study (14) .
CONCLUSIONS
The strength of our study is that some significant differentially methylated CpGs were significant in offspring of mothers with various degrees of glycemia (HAPO) [the high-glucose group in this study met new International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria for GDM; ref. 53] and also in our Gambian population (14) , thus giving credence to our results. We propose that these data suggest that DNA methylation contributes to the control of genes associated with exposure of fetuses to a diabetic environment in utero and prenatal growth restraint, as indicated by rapid postnatal catch-up growth. Our hypothesis that common gene pathways are altered is supported by the fact that the same genes associated with significant differentially methylated CpGs were significant in different in utero exposures. Many of these genes have known links to metabolic disease or growth and development and indicate candidate mechanisms involved in the developmental programming of adult disease risk. 
